Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
Open Access
- 1 January 2014
- journal article
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 35 (01) , 26-30
Abstract
Context: The exact role of the different transcript variants of BCR-ABL in the pathogenesis of chronic myeloid leukemia (CML) and their impact on prognosis is yet to be definitely enumerated. Aims: In this study, we have tried to correlate the presenting features, risk scores and treatment response with the BCR-ABL variants detected in our patients. Settings and Design: A cross-sectional unicentric hospital-based study on 80 patients diagnosed to have CML by bone marrow cytogenetics and confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR). Materials and Methods: RT-PCR for BCR-ABL was performed on consecutive patients with CML attending the CML clinic from January 2010 to December 2010.The medical charts of these patients were analyzed after a follow-up of 18 months in a retrospective manner. Statistical Analysis: Box plot and histogram was used to see the distribution of variables. t-test was performed to enumerate the difference between risk scores in two populations of patients carrying two different BCR-ABL transcript variants. Results: Nearly 56.25% of patients had b3a2 (e14a2) while 41.25% of patients showed b2a2 (e13a2) transcripts. The rest 2.5% (two patients) expressed the rare e19b2 variant. Patients with b2a2 presented with higher Sokal, Hasford and European Treatment and Outcomes Study score than their b3a2 counterpart. Different parameters such as the platelet count, leukocyte count, hemoglobin and splenomegaly showed a minor difference between the groups. More patients in the b2a2 group achieved complete hematologic response at 3 months, but it was not significant. Conclusions: Patients with b2a2 variant CML tend to present with higher risk score, but do not behave in a vastly different manner than their b3a2 counterparts.Keywords
This publication has 20 references indexed in Scilit:
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreBlood, 2011
- Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcriptHaematologica, 2009
- Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemiaNature Reviews Cancer, 2005
- The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemiaEuropean Journal of Cancer, 2000
- Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual diseaseLeukemia, 1999
- A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project GroupJNCI: Journal of the National Cancer Institute, 1998
- The breakpoint cluster region site in patients with Philadelphia chromosome–positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlationsCancer, 1995
- The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid GeneScience, 1986
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985
- The minute chromosome (Ph1) in chronic granulocytic leukemiaAnnals of Hematology, 1962